SAT0377\u2005DIFFERENCES IN CLINICAL CHARACTERISTICS, QUALITY OF LIFE, DISABILITY, AND WORK PRODUCTIVITY IN PSORIATIC ARTHRITIS PATIENTS BY GENDER: FINDINGS FROM A CROSS-SECTIONAL SURVEY IN THE US AND EUROPE

Abstract

Background: Psoriatic arthritis (PsA) prevalence is equal in men and women, though gender may play a role in driving mechanisms of PsA leading to differences in manifestations of clinical disease (1). Objectives: Assess key differences in clinical characteristics, disability, quality of life, and work productivity by gender in real-world practice. Methods: Cross-sectional survey of rheumatologists and dermatologists and their patients in France, Germany, Italy, Spain, UK, and US. Data were collected from Jun-Aug 2018 via physician-completed patient record forms and patient self-completed forms. Data were analyzed by gender. Demographic characteristics, treatment use, and clinical characteristics (Tender Joint Count [TJC], Swollen Joint Count [SJC], Body Surface Area [BSA] psoriasis) were reported by physicians, while quality of life (EQ5D and PsAID12), disability (HAQ-DI), and work productivity (WPAI) were reported by patients. Men and women were compared using parametric tests and non-parametric tests where appropriate. Results: Data were collected for 2270 patients (595 US, 1675 Europe). Demographic characteristics, time from first symptoms to diagnosis, biologic treatment, and clinical characteristics were comparable between women and men (Table 1). More women reported worse quality of life, disability, and work activity impairment than men (Table 2).Table 1 Demographic and clinical characteristics in women and men [mean (SD) or n (%)] Women Men P value n (%)Age, yearsWorking full time*, n (%)Charlson Comorbidity Index score 1047 (46.1)48.3 (13.7)206 (49.4)1.10 (0.51) 1223 (53.9)48.8 (12.8)350 (68.6)1.15 (0.58) -0.42<0.01<0.01 Time from first symptoms to diagnosis, yearsPsA duration, years 1.48 (3.53)4.87 (6.15) 1.14 (2.48)4.95 (5.79) 0.760.42 Currently receiving biologic treatment, n (%) 557 (53.2) 674 (55.1) 0.38 BSA psoriasis involvement, mean%Swollen Joint CountTender Joint CountEnthesitis, n (%)Dactylitis, n (%) 5.5 (8.4)3.2 (7.0)4.1 (5.2)59 (5.6)79 (7.5) 5.5 (8.1)3.5 (6.9)4.5 (8.0)72 (5.9)75 (6.1) 0.870.390.030.860.21 *Outside the homeTable 2 Quality of life, disability, and work productivity in women and men [mean (SD)] Women Men P value EQ5D utility scoreHAQ-DI scorePsAID12 scoreWPAI percentage of activity impairmentWPAI percentage of work time missed 0.80 (0.18)0.56 (0.60)2.66 (2.07)27.9 (22.0)4.0 (14.0) 0.82 (0.17)0.41 (0.52)2.27 (1.98)24.6 (22.4)5.8 (19.2) 0.02<0.01<0.01<0.010.62 Conclusion: In women and men with similar PsA disease activity and treatment rates, women experienced worse quality of life, greater disability, and greater work impairment, despite a lower burden of comorbidities. Reference [1] Billi AC, Kahlenberg JM, Gudjonsson JE. Sex bias in autoimmunity. Curr Opin Rheumatol. 2019 Jan;31(1):53–61. Disclosure of Interests: Laure Gossec Grant/research support from: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis-Sandoz, Pfizer, Sanofi, and UCB, Consultant for: AbbVie, Biogen, BMS, Celgene, Janssen, Lilly, MSD, Nordic Pharma, Novartis-Sandoz, Pfizer, Roche, Sanofi, and UCB, Consultant for: L Gossec has received honoraria from Celgene as investigator for this study, Jessica A. Walsh Grant/research support from: Abbvie, Pfizer, Consultant for: Abbvie, Celgene, Lilly, Novartis, Kaleb Michaud Grant/research support from: Pfizer (within past 2 years), Steve Peterson Shareholder of: Janssen, Employee of: BMS (2000-2002), Janssen (2002-present), Elizabeth Holdsworth Employee of: Adelphi Real World, Chetan Karyekar Shareholder of: J&J, Employee of: Janssen Scientific Affairs, LLC, Abbott, BMS, Novartis, Nicola Booth Employee of: Adelphi Real World, Jessalyn Kemp Employee of: Adelphi Real World, Soumya D Chakravarty Shareholder of: Johnson & Johnson, Employee of: Johnson & Johnson, Shelly Kafka Shareholder of: J&J, Employee of: J&J, Alexis Ogdie Grant/research support from: (To my university) Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Consultant for: AbbVie, Bristol-Myers Squibb, Celgene, Corrona, Eli Lilly and Company, Novartis, Pfizer, and Takeda, Consultant for: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Corrona, Eli Lilly, Novartis, Pfizer Inc, Takeda, Consultant for: Abbvie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, Takeda, Consultant for: Abbvie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, Takeda